Vaccinex is hosting a business opinion leaders luncheon on Huntington’s disease in New York City today. As part of the program,…
Articles by Ana de Barros, PhD
The European Medicines Agency (EMA) has granted orphan medicinal product designation to AMT-130, uniQure’s gene therapy candidate for…
People with Huntington’s disease in the U.K. are pushing for more open communication regarding assisted dying between clinicians, patients, and…
Taube Philanthropies, a charitable organization from the San Francisco Bay Area, in California, recently donated $750,000 to the…
The Hereditary Disease Foundation (HDF) raised $900,000 to fund research into Huntington’s disease and other brain disorders during…
The U.S. Patent and Trademark Office (USPTO) recently notified Mitochon Pharmaceuticals of its allowance on the first patent…
Three Huntington’s disease (HD) patient advocacy organizations in Europe and North America recently launched a collaborative effort to give patients…
The U.S. Food and Drug Administration (FDA) has awarded orphan drug status to uniQure’s proprietary candidate for Huntington’s disease (HD),…
GeneFo will offer a free webinar on how adding humor to Huntington’s patients’ lives can help improve their symptom…
Three entities — the Clinical Data Interchange Standards Consortium (CDISC), the Critical Path Institute (C-Path) and the CHDI Foundation (CHDI) —…